# A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors

> **NCT07682870** · PHASE1,PHASE2 · RECRUITING · sponsor: **Virogin Biotech Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection

## Key facts

- **NCT ID:** NCT07682870
- **Lead sponsor:** Virogin Biotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-04
- **Primary completion:** 2028-12-02
- **Final completion:** 2029-09-03
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682870, "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07682870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*